Drug intelligence / Profile preview

Duzhong Shuangjiang Daipaoji

Development stage: Unknown
Lead developer: Shenqi Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Duzhong Shuangjiang Daipaoji is a traditional Chinese medicine (TCM) formulation developed and marketed by Shenqi Pharmaceutical. It is prepared as a tea bag for oral infusion, primarily containing *Eucommia ulmoides* (Duzhong). The product is indicated for the management of cardiometabolic conditions, specifically targeting the reduction of both blood pressure and blood lipids, as reflected in its name 'Shuangjiang' (meaning 'double lowering'). It is a mature, approved product in the Chinese market, often used as an adjunctive therapy for hypertension and hyperlipidemia.

Brand names: Duzhong Shuangjiang Daipaoji杜仲双降袋泡剂
Other names: Duzhong Shuangjiang Tea BagEucommia Double Lowering Tea Bag

Targets

ACE (Angiotensin Converting Enzyme)

Beyond the preview

Go deeper on Duzhong Shuangjiang Daipaoji.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Duzhong Shuangjiang Daipaoji.

Explore the full profile